Open AccessEnfortumab vedotin for the treatment of patients with urothelial cancer after failure of the treatment with PD-1/PD-L1 inhibitor—cost-effectiveness analysis
Author(s) -
T. Веков,
M Draganova,
N Veleva,
Elena Daracheva,
Valentina Belcheva,
Jivko Kolev
Publication year - 2022
Publication title -
annual for hospital pharmacy
Language(s) - English
Resource type - Journals
eISSN - 2603-3852
pISSN - 2367-8763
DOI - 10.14748/ahp.v8i1.8581
Subject(s) - medicine , docetaxel , oncology , clinical trial , cost effectiveness , chemotherapy , risk analysis (engineering)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom